Updated Safety and Efficacy Results from a Phase 2 Study of ...

The AVO triplet (acalabrutinib, venetoclax, obinutuzumab) shows high efficacy in untreated CLL patients, including those with TP53 aberrant disease, achieving 78% BM-uMRD after 15 months. With a favorable safety profile and no progression observed, it's under phase 3 trial for potential new frontline therapy.